Indication and Authorized Use of Pfizer & BioNTech's COVID-19 vaccines.


Emergency uses of the vaccines have not been approved or licensed by the US Food and Drug Administration (FDA) but have been authorized by the FDA under an Emergency Use Authorization (EUA) to prevent COVID-19 in individuals aged 6 months and older for the Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

For more information, please see the full Prescribing Information and EUA Fact Sheets for Vaccination Providers available at cvdvaccine-us.com.

Medical Update on Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)

Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA

Date and Time:

14 November 2022

12:00 pm – 1:00 pm EST

15 November 2022

5:00 pm – 6:00 pm EST

16 November 2022

3:00 pm – 4:00 pm EST

COVID-19 and COVID-19 mRNA Vaccine-Related Myocarditis

Santiago Lopez, MD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA

Date and Time:

29 November 2022

12:00 pm –1:00 pm EST

01 December 2022

4:00 pm –5:00 pm EST

Neutralization of Omicron Sublineages with the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)

Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA

Date and Time:

13 December 2022

12:00 pm – 1:00 pm EST

14 December 2022

5:00 pm – 6:00 pm EST

15 December 2022

3:00 pm – 4:00 pm EST

Effectiveness of COVID-19 mRNA Vaccines, Bivalent (Original and Omicron BA.4/BA.5) Against Omicron Sublineages

Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA

Date and Time:

11 January 2023

12:00 pm – 1:00 pm EST

12 January 2023

5:00 pm – 6:00 pm EST

17 January 2023

3:00 pm – 4:00 pm EST

Select Bivalent COVID-19 Vaccine Information Presented at Recent FDA Advisory Committee Meeting

Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA

Date and Time:

13 February 2023

12:00 pm – 1:00 pm EST

14 February 2023

5:00 pm – 6:00 pm EST

15 February 2023

3:00 pm – 4:00 pm EST

COVID-19 Vaccination: Considerations for Pediatric Patients

Maria D. McColgan, MD, MSEd
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA

Date and Time:

27 February 2023

12:00 PM – 1:00 PM EST

28 February 2023

5:00 PM – 6:00 PM EST

01 March 2023

3:00 PM – 4:00 PM EST